PRECAUTIONS O
Children O
should O
be O
of O
sufficient O
body O
mass O
to O
accommodate O
the O
implantable O
pump O
for O
chronic O
infusion O
. O

Please O
consult O
pump O
manufacturer O
's O
manual O
for O
specific O
recommendations O
. O

Safety O
and O
effectiveness O
in O
pediatric O
patients O
below O
the O
age O
of O
4 O
have O
not O
been O
established O
. O

Screening O
Patients O
should O
be O
infection B-Not_AE_Candidate
-free O
prior O
to O
the O
screening O
trial O
with O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
because O
the O
presence O
of O
a O
systemic O
infection B-NonOSE_AE
may O
interfere O
with O
an O
assessment O
of O
the O
patient O
's O
response O
to O
bolus O
LIORESAL O
INTRATHECAL O
. O

Pump O
Implantation O
Patients O
should O
be O
infection B-Not_AE_Candidate
-free O
prior O
to O
pump O
implantation O
because O
the O
presence O
of O
infection B-NonOSE_AE
may O
increase O
the O
risk O
of O
surgical O
complications O
. O

Moreover O
, O
a O
systemic O
infection B-NonOSE_AE
may O
complicate O
dosing O
. O

Pump O
Dose O
Adjustment O
and O
Titration O
In O
most O
patients O
, O
it O
will O
be O
necessary O
to O
increase O
the O
dose O
gradually O
over O
time O
to O
maintain O
effectiveness O
; O
a O
sudden O
requirement O
for O
substantial O
dose O
escalation O
typically O
indicates O
a O
catheter O
complication O
( O
i O
. O
e. O
, O
catheter O
kink O
or O
dislodgement O
) O
. O

Reservoir O
refilling O
must O
be O
performed O
by O
fully O
trained O
and O
qualified O
personnel O
following O
the O
directions O
provided O
by O
the O
pump O
manufacturer O
. O

Inadvertent B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
subcutaneous I-OSE_Labeled_AE
tissue I-OSE_Labeled_AE
can O
occur O
if O
the O
reservoir O
refill O
septum O
is O
not O
properly O
accessed O
. O

Subcutaneous O
injection O
may O
result O
in O
symptoms O
of O
a O
systemic O
overdose B-NonOSE_AE
or O
early O
depletion O
of O
the O
reservoir O
. O

Refill O
intervals O
should O
be O
carefully O
calculated O
to O
prevent O
depletion O
of O
the O
reservoir O
, O
as O
this O
would O
result O
in O
the O
return O
of O
severe O
spasticity B-NonOSE_AE
and O
possibly O
symptoms O
of O
withdrawal B-NonOSE_AE
. O

Strict O
aseptic O
technique O
in O
filling O
is O
required O
to O
avoid O
bacterial O
contamination O
and O
serious O
infection B-NonOSE_AE
. O

A O
period O
of O
observation O
appropriate O
to O
the O
clinical O
situation O
should O
follow O
each O
refill O
or O
manipulation O
of O
the O
drug O
reservoir O
. O

Extreme O
caution O
must O
be O
used O
when O
filling O
an O
FDA O
approved O
implantable O
pump O
equipped O
with O
an O
injection O
port O
that O
allows O
direct O
access O
to O
the O
intrathecal O
catheter O
. O

Direct B-OSE_Labeled_AE
injection I-OSE_Labeled_AE
into I-OSE_Labeled_AE
the I-OSE_Labeled_AE
catheter I-OSE_Labeled_AE
through O
the O
catheter O
access O
port O
may O
cause O
a O
life-threatening O
overdose B-NonOSE_AE
. O

Additional O
considerations O
pertaining O
to O
dosage O
adjustment O
It O
may O
be O
important O
to O
titrate O
the O
dose O
to O
maintain O
some O
degree O
of O
muscle O
tone O
and O
allow O
occasional O
spasms B-NonOSE_AE
to O
: O
1 O
) O
help O
support O
circulatory O
function O
, O
2 O
) O
possibly O
prevent O
the O
formation O
of O
deep B-NonOSE_AE
vein I-NonOSE_AE
thrombosis I-NonOSE_AE
, O
3 O
) O
optimize O
activities O
of O
daily O
living O
and O
ease O
of O
care O
. O

Except O
in O
overdose B-NonOSE_AE
related O
emergencies O
, O
the O
dose O
of O
LIORESAL O
INTRATHECAL O
should O
ordinarily O
be O
reduced O
slowly O
if O
the O
drug O
is O
discontinued O
for O
any O
reason O
. O

An O
attempt O
should O
be O
made O
to O
discontinue O
concomitant O
oral O
antispasticity O
medication O
to O
avoid O
possible O
overdose B-NonOSE_AE
or O
adverse O
drug O
interactions O
, O
either O
prior O
to O
screening O
or O
following O
implant O
and O
initiation O
of O
chronic O
LIORESAL O
INTRATHECAL O
infusion O
. O

Reduction O
and O
discontinuation O
of O
oral O
anti-spasmotics O
should O
be O
done O
slowly O
and O
with O
careful O
monitoring O
by O
the O
physician O
. O

Abrupt O
reduction O
or O
discontinuation O
of O
concomitant O
antispastics O
should O
be O
avoided O
. O

Drowsiness O
Drowsiness B-OSE_Labeled_AE
has O
been O
reported O
in O
patients O
on O
LIORESAL O
INTRATHECAL O
. O

Patients O
should O
be O
cautioned B-NonOSE_AE
regarding I-NonOSE_AE
the I-NonOSE_AE
operation I-NonOSE_AE
of I-NonOSE_AE
automobiles I-NonOSE_AE
or O
other O
dangerous O
machinery O
, O
and O
activities O
made O
hazardous O
by O
decreased B-NonOSE_AE
alertness I-NonOSE_AE
. O

Patients O
should O
also O
be O
cautioned O
that O
the O
central B-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
depressant I-NonOSE_AE
effects I-NonOSE_AE
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
may O
be O
additive O
to O
those O
of O
alcohol O
and O
other O
CNS O
depressants O
. O

Intrathecal O
mass O
Cases O
of O
intrathecal B-OSE_Labeled_AE
mass I-OSE_Labeled_AE
at I-OSE_Labeled_AE
the I-OSE_Labeled_AE
tip I-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
implanted I-OSE_Labeled_AE
catheter I-OSE_Labeled_AE
have O
been O
reported O
, O
most O
of O
them O
involving O
pharmacy O
compounded O
analgesic O
admixtures O
. O

The O
most O
frequent O
symptoms O
associated O
with O
intrathecal B-NonOSE_AE
mass I-NonOSE_AE
are O
: O
1 O
) O
decreased B-NonOSE_AE
therapeutic I-NonOSE_AE
response I-NonOSE_AE
( O
worsening B-NonOSE_AE
spasticity I-NonOSE_AE
, O
return B-NonOSE_AE
of I-NonOSE_AE
spasticity I-NonOSE_AE
when O
previously O
well O
controlled O
, O
withdrawal B-NonOSE_AE
symptoms I-NonOSE_AE
, O
poor O
response O
to O
escalating O
doses O
, O
or O
frequent O
or O
large O
dosage O
increases O
) O
, O
2 O
) O
pain B-NonOSE_AE
, O
3 O
) O
neurological B-NonOSE_AE
deficit/ O
dysfunction I-NonOSE_AE
. O

Clinicians O
should O
monitor O
patients O
on O
intraspinal O
therapy O
carefully O
for O
any O
new O
neurological B-NonOSE_AE
signs I-NonOSE_AE
or I-NonOSE_AE
symptoms I-NonOSE_AE
. O

In O
patients O
with O
new O
neurological O
signs O
or O
symptoms O
suggestive O
of O
an O
intrathecal B-NonOSE_AE
mass I-NonOSE_AE
, O
consider O
a O
neurosurgical O
consultation O
, O
since O
many O
of O
the O
symptoms O
of O
inflammatory B-NonOSE_AE
mass I-NonOSE_AE
are O
not O
unlike O
the O
symptoms O
experienced O
by O
patients O
with O
severe O
spasticity B-Not_AE_Candidate
from O
their O
disease O
. O

In O
some O
cases O
, O
performance O
of O
an O
imaging O
procedure O
may O
be O
appropriate O
to O
confirm O
or O
rule-out O
the O
diagnosis O
of O
an O
intrathecal B-NonOSE_AE
mass I-NonOSE_AE
. O

Precautions O
in O
special O
patient O
populations O
Careful O
dose O
titration O
of O
LIORESAL O
INTRATHECAL O
is O
needed O
when O
spasticity B-NonOSE_AE
is O
necessary O
to O
sustain O
upright O
posture O
and O
balance O
in O
locomotion O
or O
whenever O
spasticity B-NonOSE_AE
is O
used O
to O
obtain O
optimal O
function O
and O
care O
. O

Patients O
suffering O
from O
psychotic B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
schizophrenia B-Not_AE_Candidate
, O
or O
confusional B-Not_AE_Candidate
states I-Not_AE_Candidate
should O
be O
treated O
cautiously O
with O
LIORESAL O
INTRATHECAL O
and O
kept O
under O
careful O
surveillance O
, O
because O
exacerbations O
of O
these O
conditions O
have O
been O
observed O
with O
oral O
administration O
. O

LIORESAL O
INTRATHECAL O
should O
be O
used O
with O
caution O
in O
patients O
with O
a O
history O
of O
autonomic B-Not_AE_Candidate
dysreflexia I-Not_AE_Candidate
. O

The O
presence O
of O
nociceptive O
stimuli O
or O
abrupt O
withdrawal B-NonOSE_AE
of O
LIORESAL O
INTRATHECAL O
( O
baclofen O
injection O
) O
may O
cause O
an O
autonomic B-NonOSE_AE
dysreflexic I-NonOSE_AE
episode I-NonOSE_AE
. O

Because O
LIORESAL O
is O
primarily O
excreted O
unchanged O
by O
the O
kidneys O
, O
it O
should O
be O
given O
with O
caution O
in O
patients O
with O
impaired B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
and O
it O
may O
be O
necessary O
to O
reduce O
the O
dosage O
. O

LABORATORY O
TESTS O
No O
specific O
laboratory O
tests O
are O
deemed O
essential O
for O
the O
management O
of O
patients O
on O
LIORESAL O
INTRATHECAL O
. O

DRUG O
INTERACTIONS O
There O
is O
inadequate O
systematic O
experience O
with O
the O
use O
of O
LIORESAL O
INTRATHECAL O
in O
combination O
with O
other O
medications O
to O
predict O
specific O
drug-drug O
interactions O
. O

Interactions O
attributed O
to O
the O
combined O
use O
of O
LIORESAL O
INTRATHECAL O
and O
epidural O
morphine O
include O
hypotension B-NonOSE_AE
and O
dyspnea B-NonOSE_AE
. O

CARCINOGENESIS O
, O
MUTAGENESIS O
, O
AND O
IMPAIRMENT O
OF O
FERTILITY O
No O
increase O
in O
tumors B-NonOSE_AE
was O
seen O
in O
rats O
receiving O
baclofen O
orally O
for O
two O
years O
. O

Adequate O
genotoxicity B-NonOSE_AE
assays O
of O
baclofen O
have O
not O
been O
performed O
. O

PREGNANCY O
There O
are O
no O
adequate O
and O
well-controlled O
studies O
in O
pregnant B-Not_AE_Candidate
women O
. O

In O
animal O
studies O
, O
baclofen O
had O
adverse O
effects O
on O
embryofetal B-NonOSE_AE
development I-NonOSE_AE
when O
administered O
orally O
to O
pregnant B-NonOSE_AE
rats O
. O

LIORESAL O
INTRATHECAL O
should O
be O
used O
during O
pregnancy B-Not_AE_Candidate
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
the I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Baclofen O
given O
orally O
increased O
the O
incidence O
of O
fetal B-NonOSE_AE
structural I-NonOSE_AE
abnormalities I-NonOSE_AE
( O
omphaloceles B-NonOSE_AE
) O
in O
rats O
. O

Reductions B-NonOSE_AE
in I-NonOSE_AE
food I-NonOSE_AE
intake I-NonOSE_AE
and O
body B-NonOSE_AE
weight I-NonOSE_AE
gain I-NonOSE_AE
were O
observed O
in O
the O
dams O
. O

Fetal B-NonOSE_AE
structural I-NonOSE_AE
abnormalities I-NonOSE_AE
were O
not O
observed O
in O
mice O
or O
rabbits O
NURSING O
MOTHERS O
In O
mothers O
treated O
with O
oral O
LIORESAL O
( O
baclofen O
USP O
) O
in O
therapeutic O
doses O
, O
the O
active O
substance O
passes O
into O
the O
milk O
. O

It O
is O
not O
known O
whether O
detectable O
levels O
of O
drug O
are O
present O
in O
milk O
of O
nursing O
mothers O
receiving O
LIORESAL O
INTRATHECAL O
. O

As O
a O
general O
rule O
, O
nursing O
should O
be O
undertaken O
while O
a O
patient O
is O
receiving O
LIORESAL O
INTRATHECAL O
only O
if O
the O
potential O
benefit O
justifies O
the O
potential O
risks O
to O
the O
infant O
. O

PEDIATRIC O
USE O
Children O
should O
be O
of O
sufficient O
body O
mass O
to O
accommodate O
the O
implantable O
pump O
for O
chronic O
infusion O
. O

Please O
consult O
pump O
manufacturer O
's O
manual O
for O
specific O
recommendations O
. O

Safety O
and O
effectiveness O
in O
pediatric O
patients O
below O
the O
age O
of O
4 O
have O
not O
been O
established O
. O

Considerations O
based O
on O
experience O
with O
oral O
LIORESAL O
( O
baclofen O
USP O
) O
A O
dose-related O
increase O
in O
incidence O
of O
ovarian B-NonOSE_AE
cysts I-NonOSE_AE
was O
observed O
in O
female O
rats O
treated O
chronically O
with O
oral O
LIORESAL O
. O

Ovarian B-OSE_Labeled_AE
cysts I-OSE_Labeled_AE
have O
been O
found O
by O
palpation O
in O
about O
4 O
% O
of O
the O
multiple B-Not_AE_Candidate
sclerosis I-Not_AE_Candidate
patients O
who O
were O
treated O
with O
oral O
LIORESAL O
for O
up O
to O
one O
year O
. O

In O
most O
cases O
these O
cysts O
disappeared O
spontaneously O
while O
patients O
continued O
to O
receive O
the O
drug O
. O

Ovarian B-NonOSE_AE
cysts I-NonOSE_AE
are O
estimated O
to O
occur O
spontaneously O
in O
approximately O
1 O
% O
to O
5 O
% O
of O
the O
normal O
female O
population O
. O

